Demonstrated Clinical Successes Across Diverse Products and Indications

BonoFill™ is transforming the treatment of bone deficiencies. Successfully implemented in two Phase II clinical studies, BonoFill™ has helped patients recover from disabilities after other treatments failed. It broadens bone grafting options, enables a swift return to normal functions, and reduces the need for revision surgeries. This could potentially cut surgery time by up to 70% and decrease hospitalization and surgery costs by over 50%. Meanwhile, MesenCure™, our therapy for inflammation and tissue damage, has shown significant effectiveness in treating severely ill patients experiencing respiratory distress. It reduced their mortality rate by an impressive 68% and shortened hospital stays of complicated patients by 9 to 10 days. This revolutionary therapy offers additional treatment options for severe ARDS patients, reduces ICU burden, and could decrease hospitalization costs by an estimated 40%.

Targeting Multi-Billion-Dollar Markets with Minimal Competition

Our breakthrough therapies, MesenCure™ and BonoFill™, have the potential to revolutionize treatment for nearly 250K patients annually in the U.S. alone, representing a nearly $100B market. MesenCure™ is set to disrupt a largely untapped market, with current treatments for respiratory distress predominantly supportive, highlighting the crucial need for curative therapies like MesenCure. By 2030, this market in the U.S. alone is projected to reach a staggering $23 billion, encompassing 691K patients annually. With its first-in-class status, MesenCure could potentially serve 118K of these patients.

BonoFill™, our innovative therapy for bone deficiencies, is poised to redefine bone grafting. By 2030, the U.S. will witness over 6.2 million bone grafting procedures, representing a $70 billion market. As the only alternative to bone auto-grafting, BonoFill offers a potentially more effective, readily available, and cost-efficient solution, aiming to treat up to 130K patients each year in the U.S. alone and many more globally.

Proprietary Platform Technology with Broad Applicability Across Various Indications

Our unique technological platform underpins the development of our leading products, BonoFill™ and MesenCure™. This platform allows for the harvesting, growth, and professionalization of cells with exceptional therapeutic potential. Our advanced technological platforms and know-how are solid foundations for developing various biotechnological products across the next-generation therapeutics spectrum addressing unmet clinical and market needs.

Significant Barriers to Entry for Potential Competitors

Our wealth of patents and unique understanding of the biology, therapeutic utility, and challenges associated with Mesenchymal Stromal Cells (MSCs) create significant barriers to entry for potential competitors. The Company holds exclusive rights in seven patent families, including twenty-eight approved patents and fifteen patent applications.

Established GMP-Compliant Production Facilities Scaled for Commercial Activity

In 2022, we established our base at the new Bonus BioGroup House in Haifa, Israel. This state-of-the-art facility is designed to comply with the GMP standards mandated by the FDA and EMA. It is dedicated to the R&D and manufacturing of our products, equipped to meet commercial demands. The Center houses two product-specific production halls and quality control labs and boasts Israel's most advanced R&D labs for cell therapy and tissue engineering.

Leadership Team Comprises Seasoned Executives and Scientists with a Proven Success Record

Our CEO, Dr. Shai Meretzki, a serial founder of multiple biotech companies, and our Executive Chairman, Yossi Rauch, formerly the Chief Economist and Manager of the Economics Department at Leumi PIA, guide our strong team. Our leadership blends experience and academic and business rigor, consistently driving groundbreaking innovations.

BonoFill and MesenCure can become viable treatment options due to their safety, ease of administration, and flexibility. BonoFill is an autologous product made from the patient's cells in a closed and highly-controlled culture system requiring minimal manual manipulation. MesenCure, as well, is manufactured using a highly controlled process from cells that do not elicit an immune response. These aspects are expected to improve the quality and safety attributes of the products. 

Our advanced technological platforms and know-how are solid foundations for developing various biotechnological products across the next-generation therapeutics spectrum addressing unmet clinical and market needs. Through many years of research and development, we have gained a unique understanding of the biology, therapeutic utility, and challenges associated with MSCs. 

A wealthy patent estate. The Company directly or through Bonus Therapeutics Ltd. (a wholly-owned subsidiary of Bonus Biogroup Ltd.) holds exclusive rights in seven patent families, including thirty-eight approved patents and seventeen patent applications.